RNA payload

An RNA payload refers to the functional ribonucleic acid sequence—such as messenger RNA (mRNA), small interfering RNA (siRNA), or microRNA (miRNA)—that serves as the active therapeutic component within a delivery vehicle (Sahin et al., 2014, Nature Reviews Drug Discovery). Unlike traditional drugs that target proteins, the RNA payload is the agent that either directs the synthesis of a therapeutic protein or selectively silences disease-associated genes (Setten et al., 2019, Nature Reviews Drug Discovery). mRNA payloads leverage the host's translational machinery to produce proteins, such as viral antigens in vaccines or missing enzymes in genetic disorders. Conversely, siRNA and miRNA payloads utilize the endogenous RNA interference (RNAi) pathway to degrade specific messenger RNA, thereby preventing the production of disease-causing proteins (Hou et al., 2021, Nature Reviews Materials). The clinical success of this approach is exemplified by the rapid development of COVID-19 mRNA vaccines and the approval of several RNAi therapies for rare diseases. Key considerations for biotech analysts include the payload's chemical modification for stability, its encapsulation in delivery systems like lipid nanoparticles (LNPs), and the management of potential immunogenic reactions to foreign nucleic acids.

Other names

Therapeutic RNARNA cargoGenetic payloadNucleic acid payloadRNA therapeutic

RNA payloads function by providing a genetic template for protein synthesis (mRNA) or by guiding the RNA-induced silencing complex (RISC) to achieve sequence-specific degradation or translational repression of target mRNA (siRNA/miRNA) (Sahin et al., 2014; Setten et al., 2019).